We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
well said keith.my sentiments exactly.very glad you have found Rosie.please give her my regards.
on a serious note i actually found heimdals summary very helpful as a reminder of the various issues and hopefully opportunities which await over the next couple of years.whether any of them come to fruition in a way which positively impacts the s/p is anyone's guess but i'm trying to remain optimistic despite the dire s/p performance
No cynicism here. I've found Rosie and am looking forward to to the future with renewed enthusiasm. Everything has been handled with tremendous professionalism and expertise so far. Good old JG has more than earned his millionaire status.
do i detect a note of cynicism keith? and who is this Rosie and why are you looking for her?
Phew....that’s ok then, everything is looking Rosie. Only 60% down st the moment. All looking good for LTHs.
Hold fast fellas, plenty of news to look forward to within the next few weeks/months:
- Update on CBD development in China
- Confirmation of completion of FDA Phase II validation study
- New launches in Greece and Romania by Recordati
- New launches in Hong Kong and Macau by Orient EuroPharma
- ATO settlement
- Update from Wanbang on application for clinical trial approval in China
- Payment receipt of US$4,000,000 from Wanbang
- Maybe also some positive news on licensing agreement(s) for North America, India, Middle East and/or the LATAM region.
It is very positive that Recordati has re-launched Fortacin™ in France, Germany, Italy, Portugal, Spain and the UK - showing commitment. Indeed, as bignose pointed out, Fortacin is a world class product - just require brand awareness.
Hang in there guys. Fantastic opportunity to pick up a few more shares at these levels.
Heimdal
Bothwell, yes, if you believe that Fortacin revenue is critical for RP's continued survival.
I can bang on about my rationale for this statement but instead I'll leave you with a quote which I've used for years when teaching pharma business development. Ironically, it's lifted from an analysis of Viagra market development:
"“The single most revealing measure of an innovation's economic value is the market's response to it.” (Alison Keith)
Bothwell,
Don't be too downhearted. I'm sure everyone who is invested here are more than disappointed in the way things have turned out. Unfortunately, like AIM, it would appear the HK market doesn't like continued bad news and companies like ours are severely punished for that.
We have a really good product which currently needs plenty of brand awareness targeted at those that need it. Unfortunately for us they chose the EMA route first rather than the FDA route and as such it has well and truly bitten everyone on the arse. I am sure once we start phase III there will be more interest from the outstanding license regions and further, once we obtain FDA approval and there is good market advertising, this will take off. We just need a little more patience.
If Pfizer had followed the same route and obtained EMA approval first with no direct to consumer marketing, they would have had the same problem. Viagra became what it is today (as well as all the other brands) because of the consumer advertising which brought awareness and through secondary media coverage that accelerated the awareness and eventually product sales. We don't get any of this with EMA approval.
The current SP drop is more than likely due to a combination of the Trump/China syndrome and the fact that, as I stated previously, there is a possibility of dilution, but that's just my take on things. Once we start getting positive news, this will pick up pretty quickly.
Your right only JM & JB can get us out of this mess. They are not doing a great job so far. SP has fallen rapidly. Will USA permission pull us out of this hole.
Bothwell,
I'm not sure why you need this sort of information from a poster with an Alias ?
He only writes to cause Chaos amongst the nervous.
Why is he still here ? Why does he still post ? Surely if he really thinks there is a problem which is causing him lack if sleep, why bother to post here. He should be writing directly the Dr Mike or JG or even JM. Makes you wonder doesn't it. I suggest you stop feeding his ego.
Cut to the chase Alquemie are we doomed.
As usual, too little detail to divine the true state of affairs, but with only around 27,000 canisters sold in H1 of the second year of launch (in a territory now comprising six countries with a combined adult male population of over 106m), safe to say that wholesalers remain understandably indifferent to the “next big revolution after Viagra" (copyright MG Wyllie 2017). Wonder if he uses a Betamax recorder to catch up with The Great British Bake Off?
And what's with this "relaunch" malarkey? Certainly no evidence of new initiatives directed by the various national subsidiaries, unless you count an exclusive distribution agreement with a certain UK-based online pharmacy.
Having used Ipsos myself for market development support, I don't doubt the quality of the survey data but it's a very strange brief. Why focus on PE patients when it's prescriber perceptions that make or break a Rx product? As my dear old grey-haired grandma used to say "Punters don't prescribe. Prescribers prescribe. And you can't promote to punters".
I strongly suspect that very few of the interviewed sufferers had any experience of Fortacin, but, if the statement that only 40% of cats prefer Fortacin is to be believed, that makes it half as popular as Whiskas and suggests a higher early discontinuation rate than for SSRIs. This does not inspire confidence in a business plan which assumes chronic use and repeat scripts.
As for HK, the delay is possibly due to sprays not being terribly popular at the moment (thinking high pressure water, tear gas, pepper, dye....). And still no update on the TFDA bridging study submission.
continuation from last post .apologies for poor spelling etc i pressed post by accident before id finshed.carrying on to say should be perfectly achievable if we can get decent marketing and decent professional recognition.the difficult questions are the time scale and the finance to get to FDA approval.this is where,imo,its key that we get another source of revenue and other investors in the interim.hence my disappointment at the yooya debacle so I'm hoping for positive news re the exciting chinese opportunity but mainly as a means of getting some revenue to keep fortacin going to FDA approval however long that takes.personally no intention of selling until we do get it.
bothwell my personal view is that is perfectly possible to get back to 0.60 HKD and indeed above.our current m/c is very low.if we can get FDA approval then imo even at 0.60HKD we would have a very small M?C for company with an EMA and FDA approved product (hopefully also indue course formal approval in china as well)whilst we may no longer be looking at a money fountain due to reluctance on the part of potential users to seek help ,which reluctance has been underestimated by regent,we need to focus on the potential from the totality of worldwide sales which we can generate once we have approval in use and china and hopefully other areas.we don't need huge volumes of sales to justify a significantly highervM?C than at present,just solid world wide sales which given the potential number of users worldwide (even if significantly discounted by reactance/embarrasment issues etc)
I get we don’t have confidence in the BOD but what can we do. Do you think we will every get the SP back to to above 60hkd.
Bothwell,
Certainly not for me, as I stated previously. I still have faith in the product. We just have to be hopeful that something can still be salvaged now it is very clear the company is run by monkeys.
The last chance shareholders had any possibility to maybe make a differencet has been and gone, so all we now have is blind faith that Dr Mike can get the FDA phase Ii approval through in the time frame they have stated, although the FDA gov website cutrently indicates otherwise.
What are we saying Bignose? Do we just give up on RP now?
agree with the bignose.from what little research i did at the time i didn't get the impression that costanzo was a yes man either which was why i was quite optimistic about the proposal.oh well looks like its back to the drawing board for the time being!
The.Italian
I Guess the reason The Loren deal didn’t gel is because maybe he is not a yes man and is quite capable of making his own decisions. And that is wherein lies the problem. The only people who will be involved are those that do not question and are capable of kowtowing, but getting paid a good bit of wedge for doing so. As such any company with Mellon in charge I doubt will go anywhere. One only has to look at his recent investments and what’s happened to them....... All IMHO of course... :-)
i suspect there is a danger in holding on to the coat tails of serial entrepreneurs.as you say bignose i don't think mellons record in recent times is that impressive (whether Juvenescence will be different only time will tell) i was badly burned in a luke johnson enterprise many years ago(belgo, the mussels and frites restaurants which he took private) so normally avoid them, but like you i found the fortacin case compelling.let us hope that if the exciting chinese opportunity(lol) comes to fruition it brings with it fresh blood to the board.doesnt look like its going to be abony and associates though now.
Bothwell,
Although he may want this to succeed, (he has plenty of egg on his face from his money fountain quotes). Maybe we need to start looking at his track record so far in this sector...... LIFE has closed down, The diabolical boot disaster that lost us nigh on 3m squid in less than that many years and he takes no action against an incompetent BOD or a CEO whose vulgar salary is incredible for such a loss making company.....WTF.
The money he invests is a mere drop in the ocean compared to his overall worth (hobby/entertainment money), so if it doesn't work out, he really wont give a monkeys arse, he will just move onto the next one and the next one, which it would appear he is trying to do now....CBD.
I still and will always have faith in the product as it is needed, but I've had it up to my neck with the constant lying and lack of professionalism from a BOD and CEO who need to be removed asap and replaced with those who are more savvy and truly are in the game for the shareholders and not just their personal gain.
I really thought the SP would have been + 60 by now.... We have an excellent product and once we get USA & China approval then it will be full steam ahead. I don’t like the way the BOD keep things to themselves. I do believe Jim Mellon wants this to succeed but wish he would talk about it.
How much lower can this SP go? No answers please, it's a rhetorical question as a result of exasperation and frustration.
whilst your approach is probably the most sensible bothwell ,the situation is exerting a sort of horrible fascination to see what happens next.two things have struck me since this morning.first mellon now has 27.5% so there is very little scope for him to finance the company in this way again if he is to avoid going over 30%. second the s/p is now so much lower that using the financing method of issuing more shares is going be even more difficult and perhaps extremely so if we get,as i think very likely, a very adverse market reaction next week to the announcement that there are no new investors. how on earth are they going to finance in a less dilutive way (as suggested by them) the exciting chinese opportunity?
Nothing surprises me anymore. Going to go into hibernation until 2020 now. Can’t be bothered looking and waiting for this Company to get its finger out.
Well I was prepared to be deflated prior to this announcement and expected a copy and paste of all the previous multiple statements of “we remain excited by the future prospect” to now “tremendously excited” and yet clearly for the shareholder holding hanging in there reading a repeat announce update and outlook review statement it is yet more frustration.
Such little cash revenue coming into the Group. Recordati had ample of time to prepare for Fortacin launch, research and marketing due to RPG long delay with canister. Yet, they also appear lacklustre with it and feel they need to relaunch it again. So, question is had they suspended it for a period? How much production of the product should there now be? How much revenue of sales royalty and WHEN will it be before received by RPG (i.e. the next 6 months results may again have very little income received)? I am not convinced that Recordati are placing much focus on this anymore which is a concern.
The trials in US and China is getting every closer, but its not much help if the professional companies marketing it are going all out to make it happen. If you go through Recordati’s results presentations there is almost very little evidence this product is on their own product radar let alone the general public or medical outlets.
RPG can put a positive spin in their outlook statement but the true fact is that Fortacin sales are not going at all to plan in any of the timescales project from the past and there is very little RPG can do anything about it as in EU Recordati pull all the strings and they can do what they like whilst RPG is impotent awaiting cash.
Hong Kong/Macau should have happened by now. If Recordati had suspended until a relaunch then transfer the stocks to HK until the next supply is produced and get some much need cash through the door from another region that has been approved many many months ago.
JG needs to get things opened up much quicker in other regions as the current cashflow situation is not enough and not acceptable if the marketing outlet in Europe isn’t pulling its finger out, RPG needs to act fast as no certainty we can rely on Recordati. This is why I am amazed that Hong Kong is taking so long, plus Middle East, plus Latin America. Open things up elsewhere JG and bl@@dy soon please.